STING1 and breast carcinoma: As expected, the results of in vitro experiments and in vivo experiment of humanized mice models showed that the combination of the AKT inhibitor MK2206 and the STING agonist ADU‐S100 powerfully boosted the antitumor immunity response and inhibited the tumor growth of endocrine‐resistant breast cancer, not in endocrine‐sensitive breast cancer.